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BACKGROUND: Cervical screening identifies many women with low-grade abnormalities. In vitro and in vivo studies have shown that
diindolylmethane (DIM) could potentially halt (cervical) carcinogenesis. We report on a randomised controlled trial of the effect of
DIM in women with low-grade cervical cytological abnormalities.
METHODS: We conducted a pragmatic double-blind, randomised controlled trial of 150mg DIM (from BioResponse DIM) or placebo
daily for 6 months in women with newly diagnosed, low-grade cytological abnormalities. Randomisation was in the ratio 2 (DIM) to 1
(placebo). All women were invited for colposcopy at 6 months with biopsy of any abnormality.
RESULTS: Of the 551 randomised women available for analysis, 9% on DIM and 12% on placebo had cervical intraepithelial neoplasia-2
(CIN2) or worse after 6-month supplementation (risk ratio (RR) 0.7 (95% confidence interval (CI): 0.4–1.2)), whereas 4.6% and
5.1%, respectively, had CIN3 or worse (RR 0.9 (95% CI: 0.4–2.0)). A total of 27.3% of women on DIM and 34.3% on placebo had no
sign of disease (negative cytology, colposcopy and human papilloma virus (HPV) tests) at 6 months (RR 0.8 (95% CI: 0.6–1.0)). Of
those HPV-positive at baseline, 69% (114 out of 166) of the DIM group were positive at 6 months compared with 61% (43 out of
71) of the placebo group: RR 1.1 (95% CI: 0.9–1.4). Diindolylmethane supplementation was well tolerated.
CONCLUSION: The results suggest that short-term DIM supplementation (150mg day1) is well tolerated, but is unlikely to have an
effect on cytology or HPV infection. Uncertainty remains regarding its effect on CIN2þ .
British Journal of Cancer (2012) 106, 45–52. doi:10.1038/bjc.2011.496 www.bjcancer.com
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In the United Kingdom, approximately 6% of cervical screening
cytology is classified as a low-grade abnormality (borderline
changes or mild dyskaryosis). At the time of this study, the
management of women with low-grade cytological abnormalities
was covered by the Cervical Screening Wales: National Service
Framework for the Cervical Screening Programme in Wales, 2009.
After one such abnormal result, women are advised to have a
repeat cytology every 6 months until they have three consecutive
negative results. If a second (in the case of mild dyskaryosis) or
third test (in the case of a borderline abnormality) is abnormal,
they are referred to colposcopy for further assessment (including
biopsy if indicated) and treatment as necessary. If a low-grade
lesion is confirmed on histology, management may be conserva-
tive, but if a high-grade lesion is identified excisional, treatment is
recommended. Both women and the health service would benefit
from the existence of an effective natural medical treatment (using
an oral preparation) for low-grade cytological lesions that would
increase regression and reduce the need for excision.
Indole-3-carbinol (I3C) and its dimer diindolylmethane (DIM)
are found in cruciferous vegetables (Ciska et al, 2009) and have
been identified as compounds that could potentially prevent or
halt carcinogenesis (Bradlow, 2008; Ahmad et al, 2010). Diindo-
lylmethane is naturally formed from I3C during acid digestion of
cruciferous vegetables and I3C supplements (Reed et al, 2006;
Ciska et al, 2009). It has been shown that DIM acts directly to cause
apoptosis in human breast, endometrial, cervical, ovarian,
prostate, and colon tumour cells in culture (Ge et al, 1996;
Bonnesen et al, 2001; Chen et al, 2001; Hong et al, 2002; Nachshon-
Kedmi et al, 2004; Azmi et al, 2008). When BioResponse DIM was
administered orally to human papilloma virus-16 (HPV-16)
transgenic mice, it was found to inhibit cervical dysplasia, alter
oestrogen metabolism, and enhance immune response (Sepkovic
et al, 2009).
The BioResponse formulation of DIM has been allowed unrest-
ricted human use as a dietary supplement in the United States of
America under the Dietary Supplement Health and Education Act
Received 2 August 2011; revised 10 October 2011; accepted 11
October 2011; published online 10 November 2011
*Correspondence: Professor P Sasieni; E-mail: p.sasieni@qmul.ac.uk
4 Joint last authors.
British Journal of Cancer (2012) 106, 45 – 52
& 2012 Cancer Research UK All rights reserved 0007 – 0920/12
www.bjcancer.com
C
li
n
ic
a
l
S
tu
d
ie
s
of 1994. The known side effects, nausea, dyspepsia, and flatulence,
are mild, reversible, and uncommon. There have been reports that
DIM may increase the severity of headaches in women who get
migraine. Many subjects also report a harmless darkening of urine
owing to excretion of coloured DIM metabolites. A previous
controlled trial reported that DIM relieved recurrent breast pain
(cyclical mastalgia) (Zeligs et al, 2005). Additionally DIM seems to
result in an increase in afternoon ketosis and may facilitate weight
loss in women on a low-carbohydrate diet (Zeligs, 2003).
The objectives of this study were to assess, in a routine screening
programme setting, the effect of 6-month supplementation with
DIM on (i) histologically proven high-grade cervical intraepithelial
neoplasia (CIN); (ii) the prevalence of cytological abnormalities;
(iii) cervical HPV infections; and (iv) to assess any side effects of
supplementation. A pre-planned sub-study monitored the effects
of DIM on weight change, headache, mastalgia, and premenstrual
syndrome.
MATERIALS AND METHODS
Study population
Women were eligible for this study if they were advised to have a
repeat screen at 6 months after a first mildly dyskaryotic smear or
a second borderline smear taken within the quality-assured
Cervical Screening Wales (CSW) programme. Recruitment to the
trial was performed between October 2004 and December 2007.
Women identified through the CSW programme as eligible were
approached using a leaflet sent through post. Interested women
were asked to contact the research team to set up an appointment
and check eligibility for the study. Women were not eligible for the
study if they were known to be pregnant, breastfeeding, HIV-
positive, taking immunosuppressive drugs or proton pump
inhibitors, under surveillance having been previously treated for
high-grade CIN, diagnosed with invasive cancer in the previous
3 years, or if there was a clinical suspicion of invasive cervical
cancer. Women were excluded from analysis if they were treated
for CIN 0–4 months after entry into the study.
The study was a double-blind, randomised, controlled, primary
prevention trial where participants were asked to take either
150mg DIM from BioResponse DIM (BioResponse, LLC, Boulder,
CO, USA) or a placebo (provided as identical oral capsules
containing calcium carbonate, maltodextrin (a complex carbo-
hydrate sourced from corn starch), and the colouring agent
Opadry NS Orange) every day for 6 months. Participants were in
the ratio 2 : 1 for DIM : placebo. Randomisation was in blocks of
random size 6 or 9 to ensure balance using an in-house computer
programme. Once entered into the study, patients were randomly
allocated a patient number that determined their supplement
allocation, and four bottles of capsules pre-labelled with their
study number were dispensed. The four bottles contained
sufficient capsules for 6 months.
Women in the trial were offered up to three appointments for
colposcopy before being re-incorporated into the CSW programme
for further follow-up. Active participation in the study ended on
12 May 2008 after the last enrolled participant attended her
6-month appointment. Histological or cytological results
taken outside of the trial were identified using the CSW database
(up until March 2009).
The South East Wales Local Research Ethics Committee
approved the research and informed written consent was obtained
from each participant before randomisation. An independent
Data and Safety Monitoring Committee was in place throughout
the trial to review study progress, potential side effects,
and efficacy. The trial is registered at ClinicalTrials.gov (Clinical-
Trials.gov, number NCT00462813) and ISRCTN (ISRCTN Register,
number 47437431).
Data collection
At the initial consultation a baseline questionnaire ascertained
information on reproductive history, diet, smoking, current
medication, history of migraine, and premenstrual symptoms.
Additionally women were weighed and a cervical sample was
obtained for HPV testing. Women received four bottles, pre-
labelled with their study number, containing sufficient capsules of
either BioResponse DIM or placebo for 6 months. The appearances
of the bottles and capsules were identical in the two arms. All clinic
personnel and study participants were blinded to treatment
assignment for the duration of the study.
Three months after entry participants were invited to attend a
nurse-led clinic at which a questionnaire was administered
regarding compliance and side effects. Women who did not attend
this visit were sent the questionnaire through post.
Six months after entry into the study, all women were offered
colposcopy. At the colposcopy visit women were weighed, any
unused were capsules retrieved, a smear was taken for liquid-based
cytology, colposcopy was performed, any visible lesions were
biopsied, and a questionnaire was completed.
Endpoint ascertainment
Histology and cytology results were cross-checked with the CSW
Programme database and any discrepancies were verified with the
original data source. Using this database we also identified further
histology or cytology results (up until March 2009) taken outside
of the trial. The intention was to study the effects of 6 months of
supplementation on cervical pathology; therefore cytology results
0–4 months after randomisation were excluded. The cytology
results presented here are from the study visit if that visit was
between 4 and 8 months after randomisation. If no such study
result is available then the earliest result (including both study and
routine tests) 4–12 months after entry is used. Histology and
colposcopy results were included if they were taken 0–3 months
after the selected cytology result.
The primary endpoint for this study was presence of disease
defined as histologically confirmed CIN2þ . Other endpoints were
high-risk human papillomavirus (HPV) positivity on a sample
taken at the 6-month visit, stratified by initial HPV result; the
presence of CIN3þ ; and post-treatment cytology result.
Smears and histological samples were read and reported within
the routine CSW programme. Cervical cytology was reported as
normal, borderline nuclear changes, mild dyskaryosis, moderate
dyskaryosis, severe dyskaryosis, possible invasion, and glandular
neoplasia. As specified in the statistical analysis plan, cytology was
analysed in three ordered categories, normal, low-grade (border-
line or mild), and high-grade (moderate, severe, or worse),
corresponding to the most common groupings for clinical
management. HPV testing was performed at the HPV laboratory,
University Hospital of Wales, by PCR enzyme immunoassay (PCR-
EIA) using GP5þ /6þ primers (Jacobs et al, 1997). Sample
adequacy was determined by inclusion of a b-globin probe. Those
samples identified as containing high-risk HPV types were then
subjected to a second PCR-EIA using individual oligonucleotide
probes to obtain genotype data. Samples were considered HPV-
positive if they were positive for a high-risk HPV both using the
consensus primers and on the type-specific assay.
Sample size
We anticipated that the incidence of CIN2 or CIN3 at 6 months
would be 7.2% in the DIM group and 12% in those taking placebo.
Based on 90% power to detect a significant difference (P¼ 0.05,
two-sided) in histology, 3000 participants were required. We had
(naively) assumed that we could recruit 3000 women over 3 years
(with 50% of eligible women participating). In practice only 11% of
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eligible women were randomised as 83% did not respond to the
initial mailed letter inviting them into the study. The trial failed to
recruit the desired number of women, and owing to lack of further
funds recruitment ended when 603 women had been enrolled.
Early stopping after recruitment of 600 patients was discussed in
the protocol and provided over 90% power for the secondary
endpoints: negative cytology at 6 months and HPV regression.
Statistical analysis
The main statistical analyses were performed on all randomised
women for whom outcome data were available.
The primary outcome was histologically confirmed CIN2þ vs
histology without CIN2þ or negative colposcopy (and no
histology).
Comparison of binary outcomes between treatment groups was
made by 2 2 tabulation and a risk ratio (RR), 95% confidence
intervals (CIs), and P-values were calculated. The significance of
trends in ordered categorical outcomes between the two treatment
groups specified in the statistical analysis plan was assessed using
the normal approximation of the Wilcoxon Rank Sum test (with an
appropriate correction for ties using the ranksum command in
STATA).
Adverse events (including serious adverse events) were
tabulated by treatment group, and RR, 95% CIs, and P-values
were calculated. Any adverse events (not considered to be serious)
previously associated with DIM, which occurred in 5% or more
women in either group, which had a 2% or more difference in
prevalence between treatment groups or which were significantly
different at the 5% significance level, were included. Events that
were non-serious, unexpected, and rare are not presented.
Analyses were performed using STATA 10 (StataCorp. 2007.
Stata Statistical Software: Release 10; College Station, TX, USA:
StataCorp LP).
RESULTS
A total of 710 women were assessed for eligibility of which 603
were randomised. The reasons for exclusion are detailed in
Figure 1. Out of the 603 women randomised, three were considered
ineligible for analysis (1 had been previously treated and 2 had
treatment within 4 months of enrolment into the study). Of the
1
5379 patients contacted by
Cervical Screening Wales
4440 No further contact
939 Responded
Not fully assessed:
54 Unable to contact
26 Time/travel
141 Did not attend 710 Patients assessed for
eligibility*
107 Ineligible:
10 Chemotherapy
31 Previous treatment
3 Breast feeding
24 Pregnant/trying
19 Proton pump inhibitor
1 Steroids
2 Other trial
1 HIV
16 Other
603 Patients randomised
R
2:1
3 Ineligible for analysis
Previous treatment
Treated outside of trial**
200 assigned to placebo
166 completed ≥1 adverse event
questionnaire
400 assigned to DIM
353 completed ≥1 adverse event
questionnaire
86 Did not attend 6-month visit:
55 DNA
9 Adverse events
2 Pregnant
1 Unable to make appointment
7 Managed elsewhere
12 Attended before 4 or after 8 months
52 Did not attend 6-month visit:
39 DNA
4 Adverse events
3 Unable to make appointment
6 Attended before 4 or after 8 months
148 Attended 6-month visit
between 4 and 8 months 
(139 HPV result at entry and
6 months)
314 Attended 6-month visit
between 4 and 8 months
(300 HPV result at entry and 
6 months)
30 Had further follow-
up in the study/CSW 
database within12
months
59 Had further follow-
up in the study/CSW 
database within 12
months
27 Had no follow-up in
the CSW database
22 Had no follow-up in 
the CSW database
373 Primary analysis 178 Primary analysis
* Recruitment stopped early: 8 patients eligibility was not assessed and patients not randomised 
** Treatment/smear performed outside of the trial and within 4 months of enrolment into study
DIM Placebo
01
1
Figure 1 Patient enrolment and compliance.
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remaining women 400 were assigned to DIM and 200 to placebo.
Of the 480 women who attended the study colposcopy, the results
of 18 are excluded because the visit was not between 4 and
8 months of entry. Of the remaining 120 women who did not
attend their 6-month study visit, 94 gave no reason, 13 withdrew
owing to adverse events, 2 became pregnant, 4 were unable to
make an appointment with the clinic, and 7 were managed
elsewhere. We were able to obtain cytology/histology results using
further cytology within 12 months available from the study or
through the CSW database for 89 of the 138 (64%) women who did
not attend their 6-month visit. The intention-to-treat analysis was
based on 373 women in the DIM group and 178 women in the
placebo group (Figure 1). A total of 439 women had adequate HPV
samples at both entry and 6 months. These numbers provided
30.3% power for the primary endpoint (CIN2þ ), 95.6% power for
the cytology endpoint, and 63.4% power for the clearance of HPV
endpoint.
There were three protocol violations. One woman had been
treated for CIN2 prior to recruitment. This woman was withdrawn
from the study within a month of randomisation as described
above. Another took a proton pump inhibitor for approximately
3 months while in the study; the trial nurses only realised this once
the woman had completed the trial. The third received colposcopy,
without treatment, at her 3-month visit (it was repeated at her
6-month visit). Neither of these two women were excluded from
the study.
Baseline characteristics did not differ between the two arms
(Table 1). Mean age was 36 years (range 19–65). Mean weight was
69 kg, with 38% of women over 70 kg at baseline. Approximately
one-third of women were on hormonal contraceptives during the
study and only 20% reported eating more than five portions a week
of cruciferous vegetables such as cabbage, cauliflower, Brussels
sprouts, or broccoli. Just over a quarter of women were current
smokers, but very few of these smoked over 20 cigarettes a day.
Approximately half the participants were enrolled with borderline
cytology and the other half with mild dyskaryosis.
A non-significantly higher proportion of women on DIM
attended their 6-month (78.5%) visit than those on placebo
(74%) (P¼ 0.217). The proportion of women who did not attend
their 6-month appointment but for whom further follow-up
cytology was identified in the study or on the CSW database was
similar in both groups (69% for DIM and 58% for placebo).
Compliance was self-reported on the 3- and 6-month question-
naires, and in addition unused capsules were counted when
returned at the 6-month visit. There were no significant differences
in compliance between the groups (data not shown).
The primary and secondary outcome results for women
included in the analysis are presented in Table 2. Of the 551
women available for analysis, 8.8% on DIM and 12.4% on placebo
were diagnosed by histology with CIN2 or worse (RR 0.70 (95% CI:
0.4–1.2)). Stratified analysis of the relative risk of CIN2 or worse
by baseline characteristics is shown in Supplementary Figure S1.
For all baseline characteristics, the difference in DIM efficacy (as
measured by relative risk) between strata was non-significant
(P40.05). The smallest relative risk (greatest DIM efficacy) was
observed in ex-smokers (RR 0.33 (95% CI: 0.11–0.97)). However,
both ex-smokers and never smokers had relative risk greater than
the overall relative risk (i.e., 40.70).
Of the women on DIM, 4.6% were diagnosed with CIN3 or worse
compared with 5.1% on placebo (RR 0.9 (95% CI: 0.4–2.0)),
whereas 50.0% and 55.7%, respectively, had negative cytology at
the end of the study (RR 1.13 (95% CI: 0.93–1.37)). 27% of women
on DIM and 34% of women on placebo had negative cytology,
colposcopy, and HPV tests at 6 months (RR 0.8 (95% CI: 0.6–1.0)).
Ninety-four percent (439 out of 462) of those women who
attended the 6-month appointment had an adequate HPV test at
entry and at 6 months. Of those positive at baseline, 69% (114 out
of 166) of the DIM group were positive at 6 months compared with
61% (43 out of 71) of the placebo group (RR 1.1 (95% CI: 0.9–1.4))
(Table 2).
Of those who were HPV-negative at baseline, 7% (10 out of 134)
on DIM and 9% (6 out of 68) on placebo became HPV-positive by
6 months (RR 0.8 (95% CI: 0.3, 2.2)). Analysis of HPV status at
6 months stratified by baseline HPV status gives a combined RR of
1.1 (95% CI: 0.9, 1.4).
More detailed cytology and histology results are presented in
Table 3. A larger proportion of women on DIM had a borderline or
worse cytology at follow-up compared with placebo (50% vs 44%,
respectively). However both groups had a similar proportion with
histologically confirmed CIN1 or worse (22% of women on DIM
and 20% on placebo).
There was no difference in the proportion of women in both
groups with persistent HPV types at 6 months. Women in the DIM
group were slightly and non-significantly less likely to develop an
incident infection with HPV-16 (2.8%) or HPV-18 (2.0%) than
women on placebo (3.7% and 4.3%, respectively) (Table 4).
Adverse events
A total of 10 serious adverse events were reported: 4 (1.0%)
occurred in the DIM group and 6 (3.0%) occurred in the placebo
Table 1 Baseline data and demographicsa
DIM (n¼ 400) Placebo (n¼ 200)
Ageb (years) 36.7±11.7 (19, 65) 35.8±12.1 (20, 65)
Weightc (kg) 68.8±14.3 69.4±14.1
Contraceptive use
Hormonal only 142 (35.5%) 76 (38.0%)
Barrier only 56 (14.0%) 28 (14.0%)
Other 34 (8.5%) 21 (10.5%)
Sterile 63 (15.8%) 22 (11.0%)
Contraception not required 99 (24.8%) 52 (26.0%)
Portions of vegetablesd per week
None 51 (12.8%) 38 (19.0%)
1–2 150 (37.5%) 59 (29.5%)
3–4 108 (27.0%) 62 (31.0%)
5+ 82 (20.5%) 38 (19.0%)
Smoking status
Never 240 (60.0%) 124 (62.0%)
Ex 47 (11.8%) 17 (8.5%)
o10 per day 54 (13.5%) 26 (13.0%)
10–19 per day 43 (10.8%) 26 (13.0%)
20+ per day 10 (2.5%) 6 (3.0%)
Migraines
No 299 (74.8%) 151 (75.5%)
Yes 99 (24.8%) 47 (23.5%)
Premenstrual syndrome
No 220 (55.0%) 107 (53.5%)
Yes 164 (41.0%) 84 (42.0%)
Mastalgia
No 238 (59.5%) 125 (62.5%)
Yes 147 (36.8%) 65 (32.5%)
Cytology
Mild 198 (49.5%) 95 (47.5%)
Borderline 202 (50.5%) 105 (52.5%)
Abbreviation: DIM¼ diindolylmethane. aValues are means±s.d. (range) or number
(%) as appropriate. bNo women were missing age. c22 (11.0%) and 30 (7.5%)
women missing weight for placebo and DIM, respectively. dVegetables include
cabbage, broccoli, or similar.
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group (RR 0.3 (95% CI: 0.1–1.2)); none were life-threatening.
Three were reported as suspected unexpected serious adverse
reactions (SUSARs): (1) A spontaneous abortion (on placebo).
(2) A woman (on DIM) with previous fibroids was admitted to
hospital because of abdominal pain: her fibroids had increased in
size since her last ultrasound some time previous to recruitment
into the trial. (3) A woman (on DIM) with a history of intermittent
inter-menstrual bleeding, which became worse during the study
and was treated by thermal ablation. Adverse events reported
during the study are presented in Table 5. Non-serious adverse
events were reported for women responding to at least one of the
3- or 6-month questionnaires on adverse events (n¼ 353 in the
DIM arm and n¼ 166 in the placebo arm). The most common
known side effect of DIM was darkening of urine, which was
reported by 31% of women on DIM compared with 10% of women
on placebo (Po0.0001). Not including darkening of urine, 69% of
women on DIM reported (one or more) non-serious adverse events
compared with 60% on placebo.
Self-reported weight gain was rare but statistically significantly
different between the DIM and placebo groups: 0.3% of women on
DIM compared with 3.0% of women on placebo (P¼ 0.03). We
examined changes in weight as measured at baseline and 6 months
and found no evidence of differences in weight change between the
two treatment groups (P¼ 0.62). There was a non-significant
differential improvement in self-reported premenstrual syndrome
(PMS), with 50% (68 out of 135) of women in the DIM arm who
had PMS at baseline and reported on it subsequently having some
improvement compared with 40% (24 out of 60) on placebo
(P¼ 0.24). There were too few women (n¼ 14) with mastalgia to
study the effect of DIM on breast pain in this trial.
DISCUSSION
Six-month supplementation with DIM did not increase the rate of
HPV clearance during the period of supplementation in women
with low-grade cytological abnormalities, nor did it increase the
proportion with negative cytology. This trial was too small to
provide narrow CIs on the effect of oral DIM on histology in
women with low-grade cytological abnormalities. Although the
results from this trial cannot exclude the possibility that 6-month
supplementation with DIM could reduce the risk of developing
CIN2 or worse by 50% (the 95% CI for the RR included 0.5), it is
Table 2 Primary and secondary outcomes at follow-up (including 6 months) for women with 6-month visita
DIMa Placeboa Relative risk (95% CI) P-value
All women n¼ 373 n¼ 178
Primary outcome
Cervical intraepithelial neoplasia grade 2+ 33 (8.8%) 22 (12.4%) 0.7 (0.4, 1.2) 0.198
Secondary outcomes
Cytology
Negative 185 (50.0%) 98 (55.7%)
Low-grade 159 (43.0%) 66 (37.5%) 0.214b
High-grade 26 (7.0%) 12 (6.8%)
Cervical intraepithelial neoplasia grade 3+ 17 (4.6%) 9 (5.1%) 0.9 (0.4, 2.0) 0.796
All negative (Cyt, Colp and HPV) 102 (27.3%) 61 (34.3%) 0.8 (0.6, 1.0) 0.092
Human papillomavirus (HPV)-positive at baselinec n¼ 166 n¼ 71
Secondary outcomes
HPV-positive at follow-up 114 (68.7%) 43 (60.6%) 1.1 (0.9, 1.4) 0.25
Human papillomavirus (HPV)-negative at baselined n¼ 134 n¼ 68
Secondary outcomes
HPV-positive at follow-up 10 (7.5%) 6 (8.8%) 0.8 (0.3, 2.2) 0.735
Combined HPV-positive at follow-up 124 (41.3%) 49 (35.3%) 1.1 (0.9, 1.4) 0.386
Abbreviations: CI¼ confidence interval; DIM¼ diindolylmethane. aValues are number (%) as appropriate. bP-value compares negative with non-negative cytology. cNumbers are
those with non-missing HPV result at 6 months; 3 missing 6-month HPV result in placebo and 3 missing 6-month HPV result in DIM. dNumbers are those with non-missing HPV
result at 6 months; 1 missing 6-month HPV result in placebo and 8 missing 6-month HPV result in DIM.
Table 3 Cytology, HPV, and histology results according to treatment
group for women with 6-month visita
DIM
(n¼ 373)
Placebo
(n¼ 178)
Cytology
Inadequate 1 (0.3%) 1 (0.6%)
Normal 185 (49.9%) 98 (55.4%)
Borderline 87 (23.5%) 40 (22.6%)
Mild 72 (19.4%) 26 (14.7%)
Moderate 19 (5.1%) 6 (3.4%)
Severe 7 (1.9%) 6 (3.4%)
Invasive carcinoma/glandular neoplasm 0 (0.0%) 0 (0.0%)
Missing 2 1
Human papillomavirus (HPV)
Negative 94 (63.5%) 179 (59.1%)
Positive 50 (33.8%) 124 (40.9%)
Missing 4 11
HPV-16-positive 18 (12.2%) 51 (16.8%)
HPV-16 or HPV-18-positive 26 (17.6%) 60 (19.8%)
Colposcopy/histology
Missing colposcopy/no biopsy 42 20
Negative colposcopyb 149 (45.0%) 66 (41.8%)
Adequate biopsy 172 (52.0%) 86 (54.4%)
Negative 57 (17.2%) 33 (20.9%)
HPV/borderline 33 (10.0%) 18 (11.4%)
CIN1 49 (14.8%) 13 (8.2%)
CIN2 16 (4.8%) 13 (8.2%)
CIN3 17 (5.1%) 9 (5.7%)
Adeno in situ 0 (0.0%) 0 (0.0%)
Missing biopsyc 10 (3.0%) 6 (3.8%)
Abbreviations: CIN¼ cervical intraepithelial neoplasia; DIM¼ diindolylmethane;
HPV¼ human papilloma virus. aValues are number (%) as appropriate. bNegative
or HPV-alone colposcopy, and negative, borderline, or mild cytology. cNo or
inadequate biopsy with Xlow-grade colposcopy or Xmoderate cytology.
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unlikely that short-term DIM supplementation has a clinically
important effect on cytology or HPV persistence. Based on these
two secondary endpoints, it seems unlikely that DIM supplemen-
tation has a substantial effect on the risk of developing CIN2 in
women with low-grade cytology.
The main limitation of this trial is the lack of power (only
30.3%) to address the primary endpoint owing to an insufficient
number of women being recruited. That said, with 603 patients
randomised, this is still (as far as we are aware) the largest
chemoprevention trial in women with either cytological or
histological cervical abnormalities; and the power to detect a
significant difference in the proportions with normal cytology at
6 months was 95.6%. It was disappointing that fewer than 20% of
those informed about the study responded, but we only had
permission from Research Ethics to approach women by post. This
trial intended to fit in with the cervical screening programme in
the United Kingdom so it was essential to recruit women very
shortly after their abnormal screen so as to be able to
accommodate 6-month supplementation without delaying their
early recall. Future studies should consider a personal approach to
potentially eligible patients by their nurse or doctor, rather than an
impersonal letter as was used in this trial. The baseline
characteristics between groups suggests that randomisation for
this trial was adequate, and although 20% of women did not attend
their 6-month appointment, we were able to trace cytology,
colposcopy, and histology results for half of these women. There is
no evidence that compliance was different between groups. Thus,
although uptake was poor, the randomisation and blinding provide
validity for our finding that 6-monthly supplementation with
150mg BioResponse DIM once daily is not effective in treating
Table 4 HPV typing results among those with a 6-month visit
Type-specific HPV-positive
at baseline
Type-specific HPV-negative
at baseline
Stratified RR of type-specific
positive at 6 months
Placebo DIM Placebo DIM OR (95% CI)
High-risk 16 N 20 72 N 128 242 0.9 (0.6, 1.3)
Persistent 13 (65.0%) 44 (61.1%) Gain 5 (3.9%) 7 (2.9%)
High-risk 18 N 13 26 N 135 288 0.7 (0.4, 1.3)
Persistent 6 (46.2%) 12 (46.2%) Gain 6 (4.4%) 5 (1.7%)
Other high-risk N 65 126 N 83 188 1.1 (0.9, 1.5)
Persistent 37 (56.9%) 82 (65.1%) Gain 6 (7.2%) 16 (8.5%)
Abbreviations: CI¼ confidence interval; DIM¼ diindolylmethane; HPV¼ human papilloma virus; OR¼ odds ratio.
Table 5 Adverse events (including deaths and serious adverse events) and secondary findings
DIMa Placeboa RR (95% CI) P-valueb
All women n¼ 400 n¼ 200
Any serious adverse Event 4 (1.0%) 6 (3.0%) 0.3 (0.1, 1.2) 0.15
Death 0 (0.0%) 0 (0.0%) — —
Women completing questionnaire n¼ 353 n¼ 166
Darkening of urine 110 (31.2%) 16 (9.6%) 3.2 (2.0, 5.3) o0.0001
Any non-serious adverse eventc 243 (68.8%) 99 (59.6%) 1.2 (1.0, 1.3) 0.011
Pre-defined adverse eventsd
Change in bowel frequency
Increased 87 (24.6%) 31 (18.7%) 1.3 (0.9, 1.9) 0.159
Decreased 2 (0.6%) 0 (0.0%) — 0.888
Diarrhoea 13 (3.7%) 4 (2.4%) 1.5 (0.5, 4.6) 0.638
Flatulence 63 (17.8%) 38 (22.9%) 0.8 (0.5, 1.1) 0.218
Headaches 63 (17.8%) 20 (12.0%) 1.5 (0.9, 2.4) 0.116
Nausea 24 (6.8%) 7 (4.2%) 1.6 (0.7, 3.7) 0.338
Skin rash 16 (4.5%) 7 (4.2%) 1.1 (0.5, 2.6) 1
Vomiting 7 (2.0%) 1 (0.6%) 3.3 (0.4, 26.5) 0.432
Other adverse eventse
Changes to the menstrual cycle 44 (12.5%) 13 (7.8%) 1.6 (0.9, 2.9) 0.149
Self-reported increase in weight 1 (0.3%) 5 (3.0%) 0.1 (0.0, 0.8) 0.028
Secondary findings
Premenstrual syndrome
Improvedf 68/135 24/60 1.3 (0.9, 1.8) 0.236
Weight changeg n¼ 243 n¼ 110
Mean (kg) 0.22 0.41 0.624
Loss of X2 kg 35/243 13/110 1.2 (0.7, 2.2) 0.634
Abbreviations: CI¼ confidence interval; DIM¼ diindolylmethane; RR¼ risk ratio. aValues are number (%). bP-values 2* 1-sided Fisher’s exact test. cAny non-serious adverse
events excluding darkening of urine. dThe total is greater than the number of women with any event owing to women with multiple types of adverse events. eOther adverse
events are those, which are common in either group or show significant difference as described under Materials and methods. fSelf-reported improvement at either 3 or 6
months (provided not worse on other visit) in those with PMS at baseline who reported on PMS at either 3 or 6 months. gIn those with a 6-month study visit between 4 and 7
months, and a valid weight at entry and 6-month visit.
Effect of DIM on low-grade cervical cytological abnormalities
A Castan˜on et al
50
British Journal of Cancer (2012) 106(1), 45 – 52 & 2012 Cancer Research UK
C
lin
ic
a
l
S
tu
d
ie
s
early cervical lesions or HPV infection. A second limitation is that
the once-daily administration maybe sub-optimal as the typical
plasma half-life for DIM from BioResponse DIM is about 3 h (Reed
et al, 2008; Heath et al, 2010); while drug kinetics may not predict
pharmacokinetics, these results suggest the need for studies of
multiple daily doses to increase tissue exposure.
It is likely that the women randomised were heterogeneous
regarding their underlying histology. This was a pragmatic trial
targeted at a group of patients who would be routinely put on
6-monthly surveillance to see whether their cytological abnorm-
ality persisted or regressed. We chose not to subject women to a
baseline biopsy because we wanted to continue ‘standard manage-
ment’ and take advantage of the 6-month window waiting for
repeat cytology. Further, a biopsy may affect the natural history of
the lesion, and had we found CIN2 or CIN3 we would have been
obliged to treat the patient and exclude her from the trial.
Other trials have studied I3C and DIM in cervical neoplasia. In a
small randomised, controlled clinical trial using I3C for 12 weeks, in
women with biopsy-confirmed high-grade CIN (HG CIN), none of
10 placebo-controlled patients had complete regression of CIN,
compared with 4 of 8 patients randomised to receive 200mgday1
I3C and 4 of 9 in the 400-mgday1 arm (Bell et al, 2000). A second
trial recruited 64 women with biopsy-proven CIN2 or CIN3
randomised 2 : 1 to BioResponse DIM (2mgkg1 per day) or
placebo for 3 months (Del Priore et al, 2010). After between 12
weeks and 12 months of follow-up, approximately two-third of the
lesions had regressed (to CIN1 or less) in both groups. There was no
evidence of a therapeutic effect in terms of histology, cytology, or
colposcopy outcome. It has been suggested that the protective
effects of indoles may be influenced by individual genetic variation
(polymorphisms) in the metabolism and elimination of isothiocya-
nates from the body (Higdon et al, 2007). The outcome of the very
small trial of I3C is inconsistent with our own findings and of the
smaller US trial using DIM. Although it is possible that the different
outcomes are due to the difference between I3C and DIM, it seems
likely to us that the dramatic results of the very small trial of I3C
were a chance finding.
There are now considerable safety data on DIM from
BioResponse DIM in humans (Zeligs et al, 2005; Reed et al,
2008; Del Priore et al, 2010; Heath et al, 2010). In the study
reported here, there was no statistically significant difference in
serious adverse events between groups; in fact a higher proportion
of women in the placebo group reported a serious adverse event.
The most common side effect of DIM was darkening of urine,
which is due to a harmless by-product. There are anecdotal reports
that DIM may increase the severity of migraine headaches.
Although this study did not have sufficient power to study
migraines, we did find a non-significant increase in reported
headaches (18% on DIM, 12% on placebo, P¼ 0.12). Even
excluding darkening of urine, women on DIM were more likely
than women on placebo to experience an adverse event, but no
single adverse event, other than darkening of urine, was reported
significantly more often in the DIM group than the placebo group.
This trial was conducted in women with borderline changes or
mildly dyskaryosis on cervical cytology in a screening programme
that managed such women by 6-month repeat cytology. Just over
50% of those recruited tested positive for HPV at entry. Where
primary cervical screening is by HPV testing, it would be valuable
to be able to offer a treatment such as DIM supplementation to
women screening positive for HPV but who are negative on a
triage test. This trial does not directly address that issue, but does
not provide any encouragement in terms of the efficacy of DIM
supplementation in such a population (the proportion with HPV
clearance was non-significantly increased in the DIM arm of this
study). There is also interest in using DIM in women with vulva
intraepithelial neoplasia. Any such study would need to address
the issue of the 3-hour half-life of BioResponse DIM. There
remains a general need for safe medical treatment of intraepithelial
neoplasia and HPV infection. This randomised, double-blind trial
suggests that 150mg DIM once daily is not effective in promoting
HPV clearance or in preventing CIN progression in women with
mildly abnormal cervical cytology.
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